BRD4770,
BRD4770,
1374601-40-7,
BRD 4770,
BRD-4770,
GTPL7016,
AOB3886,
Methyl 2-benzamido-1-(3-phenylpropyl)-1H-benzo[d]imidazole-5-carboxylate,
C25H23N3O3,
methyl 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylate,
CHEMBL3970748,
SCHEMBL16569005,
EX-A692,
CHEBI:131143,
BDBM225263,
BCP10433,
2282AH,
MFCD23143627,
s7591,
ZINC95099914,
AKOS026750266,
BRD 4770;BRD-4770,
CS-3446,
SB19344,
NCGC00351780-04,
AS-16771,
BC600603,
HY-16705,
BRD4770, >=98% (HPLC),
FT-0733814,
A14401,
J-690148,
BRD-K72264770-001-01-6,
methyl 2-benzamido-1-(3-phenylpropyl)-1H-1,3-benzodiazole-5-carboxylate,
Methyl-2-(benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylate,
2-(Benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylic acid methyl ester,
osimertinib,
D0LA0P,
BRD4470,
B4837,
C586537,
methyl 2-benzamido-1-(3-phenylpropyl)-1H-benzo[d]imidazole-5-carboxylate;methyl 2-benzamido-1-(3-phenylpropyl)-1H-benzo[d]imidazole-5-carboxylate,